XHKG9966
Market cap422mUSD
Dec 23, Last price
3.40HKD
1D
-1.73%
1Q
24.54%
IPO
-76.22%
Name
Alphamab Oncology
Chart & Performance
Profile
Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of oncology biologics. Its product pipeline includes KN046, a bispecific monoclonal antibody (BsAb) immune checkpoint inhibitor, which is in pivotal Phase III clinical trials that targets clinically-validated immune checkpoints, including programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and KN026, a next generation anti-human epidermal growth factor receptor 2 (HER2) BsAb that is in Phase II clinical trials for treating HER2-positive breast cancers and I/II clinical trial treatment of heavily pre-treated breast cancers, as well as Phase II clinical trial for HER2-positive solid tumors. The company's product pipeline also comprises KN019, a CTLA-4-based immunosuppressant fusion protein, which is in Phase II clinical trial with potential broad applications in both auto-immune diseases and oncology treatment-induced immune disorders; and KN035, an injectable PD-L1 inhibitor that has completed phase II pivotal clinical trials for deficient mismatch repair/microsatellite instability-high solid tumors, and is in Phase III pivotal trials for biliary tract cancer. In addition, its product pipeline also includes KN052 an innovative PD-L1/OX40 bispecific antibody, which is in phase Ia/Ib clinical trial for the treatment of advanced solid tumors. The company was founded in 2008 and is headquartered in Suzhou, the People's Republic of China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
Income | |||||||
Revenues | 218,774 31.12% | 166,845 14.26% | 146,021 | ||||
Cost of revenue | 542,099 | 599,385 | 561,939 | ||||
Unusual Expense (Income) | |||||||
NOPBT | (323,325) | (432,540) | (415,918) | ||||
NOPBT Margin | |||||||
Operating Taxes | 40,314 | 28,284 | |||||
Tax Rate | |||||||
NOPAT | (323,325) | (472,854) | (444,202) | ||||
Net income | (210,593) -35.35% | (325,722) -21.02% | (412,417) -3.59% | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 321,034 | 253 | 345 | ||||
BB yield | -5.04% | 0.00% | 0.00% | ||||
Debt | |||||||
Debt current | 80,498 | 190,113 | 463,814 | ||||
Long-term debt | 183,662 | 170,392 | 187,280 | ||||
Deferred revenue | 21,581 | 19,668 | 24,086 | ||||
Other long-term liabilities | (150,000) | (153,826) | |||||
Net debt | (1,143,076) | (989,872) | (1,334,390) | ||||
Cash flow | |||||||
Cash from operating activities | (202,839) | (300,308) | (320,600) | ||||
CAPEX | (36,184) | (129,651) | (158,119) | ||||
Cash from investing activities | (18,107) | 850,756 | 574,264 | ||||
Cash from financing activities | 218,072 | (310,902) | 363,902 | ||||
FCF | (260,423) | (550,445) | (589,743) | ||||
Balance | |||||||
Cash | 1,407,236 | 1,350,377 | 1,985,484 | ||||
Long term investments | |||||||
Excess cash | 1,396,297 | 1,342,035 | 1,978,183 | ||||
Stockholders' equity | (2,380,582) | (2,132,350) | (1,806,628) | ||||
Invested Capital | 4,331,355 | 3,924,750 | 4,208,533 | ||||
ROIC | |||||||
ROCE | |||||||
EV | |||||||
Common stock shares outstanding | 959,899 | 936,502 | 935,486 | ||||
Price | 6.64 -38.52% | 10.80 -20.59% | 13.60 -18.47% | ||||
Market cap | 6,373,729 -36.98% | 10,114,222 -20.50% | 12,722,610 -17.96% | ||||
EV | 5,230,653 | 9,160,203 | 11,428,061 | ||||
EBITDA | (254,207) | (377,352) | (374,816) | ||||
EV/EBITDA | |||||||
Interest | 12,179 | 14,206 | 13,182 | ||||
Interest/NOPBT |